View Item 

Show simple item record

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

dc.contributor.authorHiggins, Peter D.R.en_US
dc.contributor.authorRubin, D. T.en_US
dc.contributor.authorKaulback, K.en_US
dc.contributor.authorSchoenfield, P. S.en_US
dc.contributor.authorKane, Sunanda V.en_US
dc.date.accessioned2010-06-01T21:29:10Z
dc.date.available2010-06-01T21:29:10Z
dc.date.issued2009-02en_US
dc.identifier.citationHIGGINS, P. D. R.; RUBIN, D. T.; KAULBACK, K.; SCHOENFIELD, P. S.; KANE, S. V. (2009). "Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares." Alimentary Pharmacology & Therapeutics 29(3): 247-257. <http://hdl.handle.net/2027.42/74543>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74543
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18945258&dopt=citationen_US
dc.format.extent270802 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2009 Blackwell Publishing Ltden_US
dc.titleSystematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flaresen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother† Department of Internal Medicine, University of Chicago Medical Center, Chicago, IL, USAen_US
dc.contributor.affiliationother† Research in Practice, Toronto, ON, Canadaen_US
dc.contributor.affiliationother§ Division of Gastroenterology, Ann Arbor Veterans Affairs Medical Center and Center for Excellence in Health Services Research, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother¶ Division of Gastroenterology, Mayo Clinic, Rochester, MN, USAen_US
dc.identifier.pmid18945258en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74543/1/j.1365-2036.2008.03865.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2008.03865.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceCramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218 – 24.en_US
dc.identifier.citedreferenceMurphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003; 157: 249 – 55.en_US
dc.identifier.citedreferenceLoghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 155 – 71.en_US
dc.identifier.citedreferencePeura D. Helicobacter pylori: rational management options. Am J Med 1998; 105: 424 – 30.en_US
dc.identifier.citedreferenceDiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794 – 811.en_US
dc.identifier.citedreferenceWHO. Adherence to Long-Term Therapies. Evidence for Action [Internet], Vol. 2008. Geneva: World Health Organization, 2003.en_US
dc.identifier.citedreferenceRudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130: 572 – 9.en_US
dc.identifier.citedreferenceMorris A, Brennan G, MacDonald T, Donnan P. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000; 49: A76.en_US
dc.identifier.citedreferenceClaxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296 – 310.en_US
dc.identifier.citedreferenceEdiger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease [ see comment ]. Am J Gastroenterol 2007; 102: 1417 – 26.en_US
dc.identifier.citedreferenceCerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13: 1244 – 9.en_US
dc.identifier.citedreferenceLopez SR, Bermejo F, Carrera E, Perez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 249 – 57.en_US
dc.identifier.citedreferenceShale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191 – 8.en_US
dc.identifier.citedreferenceSewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease [ see comment ]. Am J Gastroenterol 2003; 98: 1535 – 44.en_US
dc.identifier.citedreferenceBernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 2165 – 9.en_US
dc.identifier.citedreferenceNigro G, Angelini G, Grosso SB, Caula G, Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 66 – 8.en_US
dc.identifier.citedreferencevan Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333 – 6.en_US
dc.identifier.citedreferenceKane SV. Systematic review: adherence issues in the treatment of ulcerative colitis [Review] [59 refs]. Aliment Pharmacol Ther 2006; 23: 577 – 85.en_US
dc.identifier.citedreferenceKane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39 – 43.en_US
dc.identifier.citedreferenceMoody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179 – 83.en_US
dc.identifier.citedreferenceRubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005; 100: 1354 – 6.en_US
dc.identifier.citedreferenceRubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008; 14: 265 – 74.en_US
dc.identifier.citedreferenceVelayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941 – 9.en_US
dc.identifier.citedreferenceVelayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345 – 53.en_US
dc.identifier.citedreferenceSteiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988; 26: 814 – 23.en_US
dc.identifier.citedreferenceHall NJ, Rubin GP, Hungin APS, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol. 2007; 7: 20.en_US
dc.identifier.citedreferenceLoftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 1107 – 13.en_US
dc.identifier.citedreferenceKlugmann HJ, Giehler B, Lohmann D, Schiedewitz W. Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration [German]. Gastroenterol J 1990; 49: 160 – 4.en_US
dc.identifier.citedreferenceBokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Aliment Pharmacol Ther 2007; 26: 217 – 25.en_US
dc.identifier.citedreferenceCerveny P, Lukas M, Bortlik M, Kubena A, Vlcek J Non-adherence to medicamentuous treatment of inflammatory bowel disease and its most frequent forms. Cesk Gastroenterol Hepatol 2006; 60: 207 – 12 [Czech].en_US
dc.identifier.citedreferenceBertomoro P, Vettorato M, Mazzocco K, Rumiati R, Sturniolo G, D’Inca R. Adherence to Medication in Inflammatory Bowel Disease Patients. Digestive Disease Week, Vol. 132. Washington, DC: American Gastroenterological Association, 2007: A344.en_US
dc.identifier.citedreferenceMackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 1006 – 12.en_US
dc.identifier.citedreferenceOliva-Hemker MM, Abadom V, Cuffari C, Thompson RE. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 180 – 4.en_US
dc.identifier.citedreferenceWaters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005; 19: 235 – 44.en_US
dc.identifier.citedreferenceKane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170 – 3.en_US
dc.identifier.citedreferenceHarvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 514.en_US
dc.identifier.citedreferenceTruelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041 – 8.en_US
dc.identifier.citedreferenceKane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008; 53: 1020 – 4.en_US
dc.identifier.citedreferenceKane S, Shaya F, El-Khoury A. Poor compliance with 5-ASA therapy in patients with gastrointestinal disorders increases the burden on healthcare services: a retrospective survey in Maryland, USA. In: America CsaCFo, ed. Advances in IBD, Vol. 13. Miami, FL: Crohn’s and Colitis Foundation of America, 2007: 664.en_US
dc.identifier.citedreferenceFendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001; 7: 861 – 7.en_US
dc.identifier.citedreferenceFendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med 2007; 22: 890 – 1.en_US
dc.identifier.citedreferenceRosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005; 143: 89 – 99.en_US
dc.identifier.citedreferenceLevy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 1733 – 42.en_US
dc.identifier.citedreferenceKane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97: 1853.en_US
dc.identifier.citedreferenceKripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540 – 50.en_US
dc.identifier.citedreferenceEisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881 – 4.en_US
dc.identifier.citedreferenceBrun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22: 266 – 72.en_US
dc.identifier.citedreferenceKardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005; 7: 722 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2008.03865.x.pdf
Size:
264.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.